RxDoctor Payments Data

Suresh Seshan, MD

Internal Medicine · McCordsville, INNPI 1689937427

Payments from drug & device makers

$1,850in general payments, 2019–2025

Across 106 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$397
  • Lilly USA, LLC$204
  • AstraZeneca$166
  • Exact Sciences$153
  • Amgen$133
  • Neurocrine Biosciences, Inc.$132
  • plus $664 from 18 others

What the payments were for

  • Food & beverage$1,83899%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,850 in reported general payments places this provider in the 80th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$160,922
Medicare patients
259
Services billed
2,487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban64$95,681
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$55,441
OzempicSemaglutide24$45,158
RybelsusSemaglutide20$41,078
XareltoRivaroxaban22$35,737
JanuviaSitagliptin Phosphate18$28,914
AbrysvoRsv Vacc, Pref A And Pref B/Pf88$27,593
JardianceEmpagliflozin15$24,176
Praluent PenAlirocumab18$19,519
Breo ElliptaFluticasone/Vilanterol37$18,035
FarxigaDapagliflozin Propanediol15$16,053
ShingrixVaricella-Zoster Ge/As01b/Pf28$6,165
Atorvastatin Calcium586$5,097
Duloxetine Hcl107$3,812
Tamsulosin Hcl191$3,297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo, Paxlovid$116$124,704166 claims
Novo NordiskOzempic, Rybelsus$397$86,23544 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$102$79,640111 claims
Johnson & JohnsonXarelto$13$35,73722 claims
MerckJanuvia$12$28,91418 claims
Boehringer IngelheimJardiance$19$24,17615 claims
AstraZenecaFarxiga$166$16,05315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in McCordsville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →